Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

DRUG2 trials

Sponsors

Bayer, Retina Consultants of Orange County

Conditions

Diabetic Macula Edema (DME)Diabetic Macular Edema (DME)Neovascular Age-related Macular Degeneration (nAMD)Visual Impairment

Phase 4

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

RecruitingNCT06662994

Retina Consultants of Orange CountyDiabetic Macular Edema (DME)

Start: 2025-07-07End: 2027-08-15Target: 15Updated: 2025-07-10

Unknown Phase

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Active, not recruitingNCT06075147

BayerDiabetic Macula Edema (DME), Neovascular Age-related Macular Degeneration (nAMD), Visual Impairment

Start: 2024-02-15End: 2028-01-31Target: 2500Updated: 2026-06-30

Related Papers

SPECTRUM: Week 24 data for aflibercept 8 mg indicate improvements in patients with treatment-naïve nAMD and stable outcomes in patients with previously treated nAMD

German Medical Science (German Research Foundation)2026-06-17